Associated Papers
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
Waliany S et al.
Cancer Medicine, 2024
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J et al.
The Oncologist, 2015
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Fan YX et al.
The Journal of Biological Chemistry, 2013
Select a paper to view details